ASLAN Pharmaceuticals Limited

Equities

ASLN

US04522R2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
0.4025 ^USD	-2.35%		-11.94%	-22.91%

May. 08	Asian Equities Traded in the US as American Depositary Receipts Trend Slightly Lower in Wednesday Trading	MT
May. 07	Asian Equities Traded in the US as American Depositary Receipts Drop Sharply in Tuesday Trading	MT

Aslan Pharmaceuticals Limited Announces the Change of Nomination Committee Members

July 26, 2019 at 03:06 am EDT

ASLAN Pharmaceuticals Limited announced the change of nomination committee members, Abel Ang /Director Representative of ASLAN Pharmaceuticals Limited, Jerome Shen/Director of ASLAN Pharmaceuticals Limited replaced by Robert E. Hoffman/Independent director of ASLAN Pharmaceuticals Limited as member of nomination committee, effective July 26, 2019.

Latest news about ASLAN Pharmaceuticals Limited

Asian Equities Traded in the US as American Depositary Receipts Trend Slightly Lower in Wednesday Trading	May. 08	MT
Asian Equities Traded in the US as American Depositary Receipts Drop Sharply in Tuesday Trading	May. 07	MT
Aslan Pharmaceuticals to Present Additional Data from Interim Analysis of Trek-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event	May. 07	CI
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Higher in Monday Trading	May. 06	MT
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading, End Week Over 2% Higher	May. 03	MT
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading	May. 02	MT
ASLAN Pharmaceuticals Announces Expansion of its Collaboration with Zenyaku Kogyo Co., Ltd. to Investigate Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics	May. 02	CI
Asian Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	May. 01	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note in Monday Trading	Apr. 29	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.5%	Apr. 26	MT
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading	Apr. 25	MT
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 23	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher	Apr. 22	MT
ASLAN Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients	Apr. 22	CI
Asian Equities Traded in the US as American Depositary Receipts Fall Again in Friday Trading	Apr. 19	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Apr. 18	MT
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading	Apr. 17	MT
Financial, Telecoms Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	Apr. 16	MT
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	Apr. 15	MT
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading	Apr. 12	MT
ASLAN Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 12	CI
ASLAN Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Apr. 12	CI
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Apr. 11	MT
Tech, Auto Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	Apr. 09	MT
Asian Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading, End Week Lower	Apr. 05	MT

Chart ASLAN Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - American Thoracic Society Conference - Poster No 13753

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.4025 USD

Average target price

9.5 USD

Spread / Average Target

+2,260.25%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ASLAN PHARMACEUTICALS LIMITED	-22.91%	9.11M
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B
ARGENX SE	-2.53%	23.46B
BIONTECH SE	-14.60%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-8.83%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B
VIKING THERAPEUTICS, INC.	+329.39%	8.81B

Bio Therapeutic Drugs